Tolerance Study of the Silicone Bands on Medical Compression Stockings
- Conditions
- Skin Lesions
- Interventions
- Device: Innothera's brand StockingsOther: Stockings other than Innothera's brand
- Registration Number
- NCT01486225
- Lead Sponsor
- Laboratoires Innothera
- Brief Summary
The purpose of this study is to identify the nature of skin lesions that develop on contact with the grip-top bands of medical compression stockings, which are composed mainly of silicone.
- Detailed Description
To identify the nature of lesions the investigator will analyse results of the biopsys, microbiological analyses, dermatological tests.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 3
- Subjects who notified a health care professional (doctor or pharmacist) of an incident with a grip-top bands compression stocking, regardless of brand and model.
- Subjects presenting skin lesions caused by the contact with silicone-containing grip-top bands of medical compression stockings (all brands combined).
- Subjects for whom the incriminated stockings provide class 2 compression or higher.
- Subjects covered by French national health insurance.
- Subjects who give their written informed consent and who accept the constraints of the study.
- Known allergy to local anesthetics (lidocaine, etc.).
- History of anaphylactic shock.
- Ongoing antihistamine treatment or having taken during the week before inclusion.
- Patient on ongoing systemic corticosteroids or having taken corticosteroids in the month before inclusion.
- Patient having used a topical corticosteroid in the area where the patch tests or prick tests will be performed during the week before inclusion.
- Phototherapy or sun exposure in the 30 days preceding the skin tests (on the back).
- Patient having concomitantly used compression stockings and a topical corticosteroid on the thighs in the 48 hours preceding lesion onset.
- List of diseases which will prevent a subject from participating in the study:
- acquired, infectious or drug-induced congenital immunosuppression (systemic corticosteroid therapy, immunosuppressives, chemotherapy),
- Congenital bullous disorder (congenital epidermolysis bullosa) or acquired bullous disorder (pemphigus, pemphigoid, dermatitis herpetiformis, linear IgA dermatosis, etc.).
- Patients with an ongoing or previous history of mental or psychiatric disorder or condition or any other factor interfering with the ability to give informed consent.
- Any major systemic disease making the conduct of the study or the interpretation of the results difficult.
- Patients with ongoing or previous history of decompensated heart failure.
- Chemotherapy or active cancer.
- Pregnancy.
- Patients participating in an ongoing clinical trial or in the exclusion period of a previous trial.
- Persons deprived of their liberty by judicial or administrative decision or persons hospitalized without their consent.
- Legally protected adults under guardianship.
- If the patient accepts the biopsy proposed in the study:
- Patient for whom a skin biopsy is contra-indicated or requiring antibiotic prophylaxis,
- Anticoagulant taken during the 24 hours before inclusion.
- Subject with history of allergy to natural or synthetic latex, chlorhexidine, known healing disorder and/or viral diseases transmissible through the blood documented by the preliminary clinical exam.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Innothera's brand Stokings Innothera's brand Stockings Innothera's branded grip-top silicone band stokingc Other than Innothera's brand Stockings other than Innothera's brand -
- Primary Outcome Measures
Name Time Method nature and outcome of skin lesion caused by the silicone from the grip-top band of medical stockings within 5 days from skin lesion started Patient will be followed during 5 days from the time that lessions occurs
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Hôpitaux de Brabois CHU de Nancy
🇫🇷Nancy, France